Johnson & Johnson Announces $5.5 Billion Talc Lawsuit Settlement Plan
Share this article
Company Continues to Deny Allegations
Despite agreeing to the settlement, Johnson & Johnson maintains that its talc-based products are safe and do not cause cancer. The healthcare giant stated that the settlement should not be interpreted as an admission of liability but rather as a practical decision to end lengthy litigation and focus on its healthcare business.
The company has consistently cited scientific studies supporting the safety of its talc products while denying allegations that asbestos-contaminated talc caused ovarian cancer.
Long-Running Legal Battle
The talc litigation has been one of the most closely watched legal battles involving a global healthcare company. Thousands of women alleged that long-term use of Johnson's Baby Powder and other talc-based products led to ovarian cancer.
Over the years, Johnson & Johnson attempted several legal strategies, including multiple bankruptcy-related proposals through subsidiaries, to resolve the claims collectively. Those efforts were rejected by U.S. courts, forcing the company to pursue alternative settlement negotiations.
Settlement Structure
Under the proposed agreement:
Johnson & Johnson would pay up to $5.5 billion to eligible claimants.
Initial payments of up to $3 billion are expected to begin in 2027.
Remaining payments would be made in subsequent years.
The settlement requires participation from at least 95% of claimants before becoming final.
Previous Product Changes
Although the company continues to defend the safety of its products, Johnson & Johnson stopped selling talc-based baby powder in the United States and Canada in 2020 before discontinuing it globally in 2022. The company replaced the product with a cornstarch-based version as litigation continued.
Impact on Johnson & Johnson
If finalized, the settlement would remove one of the largest legal uncertainties hanging over Johnson & Johnson. Investors have generally viewed the agreement as a significant step toward closing a costly chapter that has affected the company's reputation and financial planning for years.
What Happens Next?
The proposed settlement is still subject to participation requirements and legal procedures before it becomes effective. If sufficient claimants accept the offer, it could resolve nearly all remaining U.S. ovarian cancer lawsuits involving Johnson & Johnson's talc products while allowing the company to move forward after years of litigation.